髓源性抑制细胞在肺癌中的研究进展  

Research progress of myeloid-derived suppressor cells in lung cancer

作　　者：刘洋洋[1] 谷飞飞[1] 梁金燕[1] 刘莉[1] 

机构地区：[1]华中科技大学同济医学院附属协和医院肿瘤中心,武汉430022

出　　处：《实用肿瘤学杂志》2016年第3期257-261,共5页Practical Oncology Journal

基　　金：国家自然科学基金资助项目(81372260)

摘　　要：髓源性抑制细胞(Myeloid-derived suppressor cells,MDSCs)是一群来白骨髓不成熟的异质性细胞,表型及成分复杂,在肿瘤微环境中发挥免疫抑制功能,并主要抑制T细胞免疫应答。在肺癌的发生、发展过程中,多种异常表达的细胞因子促进MDSCs增殖与激活,MDSCs活化后参与形成抑制性肿瘤免疫微环境,从而促进肿瘤细胞生长。监测MDSCs的数量与功能变化对评估肺癌的预后有重要意义。一系列针对MDSCs的干预措施在肺癌治疗中获得了重大进展,也为肺部原发及转移瘤的预防带来了希望。Myeloid-derived suppressor cells（MDSCs）are a heterogeneous mixture of immature myeloid cells,with complex phenotype and composition,harboring the ability of immune suppression in tumor microenvironment,and they mainly inhibit the function of T cells.In the development and progression of lung caner,elevated number of function activated MDSCs,arisen by various abnormal expressing cytokines,take part in tumor immune suppression microenvironment establishing so that malignant cells growth can be accelerated.Monitoring the quantity and function of MDSCs plays an important role in assessing lung neoplasm prognosis.Benefits for lung carcinoma treatment have been proved from a series of intervening measure aiming to impact MDSCs.Moreover,these means also produced a promising prospect for the prevention of primary and metastatic lung cancer.

关 键 词：肺肿瘤 髓源性抑制细胞 肿瘤免疫微环境 

分 类 号：R734.2[医药卫生—肿瘤]